Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
Zacks Investment Research on MSN1d
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits FailureThis week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...
A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the ...
The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...
The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without ...
The findings showed that fitusiran lowers antithrombin levels to enhance thrombin generation and restore hemostasis in ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved fitusiran (Qfitlia) as prophylaxis to prevent or reduce bleeding episodes in adults and children ages ...
Dose and frequency should be adjusted based on antithrombin activity, using the Innovance Antithrombin companion diagnostic test. The Food and Drug Administration (FDA) has approved Qfitlia ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback